<DOC>
	<DOCNO>NCT00743652</DOCNO>
	<brief_summary>This study evaluate safety , immunogenicity impact 13-valent Pneumococcal conjugate vaccine Alaskan Native Children .</brief_summary>
	<brief_title>Study Evaluating Impact 13-valent Pneumococcal Conjugate Vaccine ( 13vPnC ) Alaskan Native Children .</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female infant 6 week &lt; 5years age good health , available entire study period reachable phone , parent able complete relevant study procedure . Infants receive Prevnar eligible participate , require . Infants participate blood draw must live specific identify area ( Yukon Kuskokwim Delta region ) Contraindication vaccination pneumococcal vaccine allergic reaction vaccine vaccine relate component , immune deficiency , bleed disorder major know congenital malformation .</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>13 valent Pneumococcal Conjugate Vaccine</keyword>
	<keyword>Antibody Response</keyword>
	<keyword>safety</keyword>
	<keyword>Alaskan Native Children</keyword>
</DOC>